EASL 2022 News from the International Liver Congress 2022Read our summary bulletin of news from the conference in English, Spanish, Russian, French and Portuguese. Dr Kosh Agarwal discusses results of the REEF-2 study at the International LIver Congress. Photo © Steve Forrest & Andrew McConnell / EASL.New & experimental hepatitis B treatmentsExperimental hepatitis B combination suppresses key marker but fails to achieve functional cure. Liver transplantsShort-course treatment prevents hepatitis C after organ transplant. infohep news New and experimental treatments for hepatitis B Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies Keith Alcorn / 29 June 2022 Bepirovirsen, an experimental drug with a novel mode of action, suppressed hepatitis B surface antigen below the limits of detection in approximately 30% of patients after 24 weeks of treatment and ... Hepatitis D Bulevirtide leads to sustained improvement for people with hepatitis D Liz Highleyman / 28 June 2022 The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ... New and experimental treatments for hepatitis B Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure Keith Alcorn / 27 June 2022 People with hepatitis B who received a combination of experimental drugs as well as their standard treatment for 48 weeks were significantly less likely to have high levels of hepatitis B surface ... Treatment for previous non-responders & relapsers Re-treatment of hepatitis C is highly effective after the first combination fails Keith Alcorn / 24 June 2022 Two combinations proved highly effective in curing hepatitis C in people who had experienced the failure of a previous combination containing an NS5A inhibitor, studies in Europe and New Zealand show. The findings, ... Treatment in liver transplanted Short-course treatment prevents hepatitis C after organ transplant Keith Alcorn / 24 June 2022 A seven-day course of direct-acting antiviral treatment started hours before an organ transplant prevented hepatitis C infection in everyone who received a transplant from a donor with hepatitis C, researchers from the Mayo ... Life after the cure People cured of hepatitis C remain at higher risk of death due to liver- and drug-related causes Keith Alcorn / 24 June 2022 People who have been cured of hepatitis C remain at higher risk of dying from liver-related causes than the general population, but their risk of cardiovascular events goes down after being cured, ... View more > Editors' picks from other sources Acute hepatitis outbreak swells to nearly 900 cases; global data shows ‘mixed picture’ Healio / 24 June 2022 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive